rs1042396

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_000152.5(GAA):​c.1581G>A​(p.Arg527Arg) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.257 in 1,613,658 control chromosomes in the GnomAD database, including 56,191 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.20 ( 3863 hom., cov: 33)
Exomes 𝑓: 0.26 ( 52328 hom. )

Consequence

GAA
NM_000152.5 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:15

Conservation

PhyloP100: 0.480

Publications

31 publications found
Variant links:
Genes affected
GAA (HGNC:4065): (alpha glucosidase) This gene encodes lysosomal alpha-glucosidase, which is essential for the degradation of glycogen to glucose in lysosomes. The encoded preproprotein is proteolytically processed to generate multiple intermediate forms and the mature form of the enzyme. Defects in this gene are the cause of glycogen storage disease II, also known as Pompe's disease, which is an autosomal recessive disorder with a broad clinical spectrum. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2016]
GAA Gene-Disease associations (from GenCC):
  • glycogen storage disease II
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), PanelApp Australia, ClinGen, G2P
  • glycogen storage disease due to acid maltase deficiency, infantile onset
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
  • glycogen storage disease due to acid maltase deficiency, late-onset
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.79).
BP6
Variant 17-80110970-G-A is Benign according to our data. Variant chr17-80110970-G-A is described in ClinVar as Benign. ClinVar VariationId is 92466.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=0.48 with no splicing effect.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.275 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GAANM_000152.5 linkc.1581G>A p.Arg527Arg synonymous_variant Exon 11 of 20 ENST00000302262.8 NP_000143.2 P10253

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GAAENST00000302262.8 linkc.1581G>A p.Arg527Arg synonymous_variant Exon 11 of 20 1 NM_000152.5 ENSP00000305692.3 P10253

Frequencies

GnomAD3 genomes
AF:
0.204
AC:
30958
AN:
151984
Hom.:
3865
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0633
Gnomad AMI
AF:
0.214
Gnomad AMR
AF:
0.236
Gnomad ASJ
AF:
0.254
Gnomad EAS
AF:
0.117
Gnomad SAS
AF:
0.212
Gnomad FIN
AF:
0.243
Gnomad MID
AF:
0.266
Gnomad NFE
AF:
0.278
Gnomad OTH
AF:
0.223
GnomAD2 exomes
AF:
0.232
AC:
58151
AN:
251098
AF XY:
0.237
show subpopulations
Gnomad AFR exome
AF:
0.0585
Gnomad AMR exome
AF:
0.231
Gnomad ASJ exome
AF:
0.252
Gnomad EAS exome
AF:
0.119
Gnomad FIN exome
AF:
0.235
Gnomad NFE exome
AF:
0.276
Gnomad OTH exome
AF:
0.249
GnomAD4 exome
AF:
0.263
AC:
384357
AN:
1461556
Hom.:
52328
Cov.:
48
AF XY:
0.262
AC XY:
190598
AN XY:
727070
show subpopulations
African (AFR)
AF:
0.0608
AC:
2037
AN:
33478
American (AMR)
AF:
0.232
AC:
10379
AN:
44710
Ashkenazi Jewish (ASJ)
AF:
0.254
AC:
6644
AN:
26136
East Asian (EAS)
AF:
0.120
AC:
4760
AN:
39700
South Asian (SAS)
AF:
0.217
AC:
18720
AN:
86256
European-Finnish (FIN)
AF:
0.232
AC:
12339
AN:
53208
Middle Eastern (MID)
AF:
0.257
AC:
1484
AN:
5768
European-Non Finnish (NFE)
AF:
0.281
AC:
312872
AN:
1111912
Other (OTH)
AF:
0.250
AC:
15122
AN:
60388
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.474
Heterozygous variant carriers
0
17982
35963
53945
71926
89908
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
10220
20440
30660
40880
51100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.203
AC:
30948
AN:
152102
Hom.:
3863
Cov.:
33
AF XY:
0.202
AC XY:
14983
AN XY:
74340
show subpopulations
African (AFR)
AF:
0.0632
AC:
2623
AN:
41524
American (AMR)
AF:
0.235
AC:
3598
AN:
15290
Ashkenazi Jewish (ASJ)
AF:
0.254
AC:
881
AN:
3468
East Asian (EAS)
AF:
0.117
AC:
605
AN:
5166
South Asian (SAS)
AF:
0.211
AC:
1016
AN:
4822
European-Finnish (FIN)
AF:
0.243
AC:
2570
AN:
10574
Middle Eastern (MID)
AF:
0.272
AC:
80
AN:
294
European-Non Finnish (NFE)
AF:
0.278
AC:
18914
AN:
67942
Other (OTH)
AF:
0.221
AC:
466
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
1236
2472
3709
4945
6181
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
324
648
972
1296
1620
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.244
Hom.:
3375
Bravo
AF:
0.199
Asia WGS
AF:
0.152
AC:
528
AN:
3478
EpiCase
AF:
0.286
EpiControl
AF:
0.286

ClinVar

Significance: Benign
Submissions summary: Benign:15
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Glycogen storage disease, type II Benign:6
Jun 10, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Aug 01, 2017
Phosphorus, Inc.
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Nov 20, 2019
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

not specified Benign:5
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Sep 04, 2018
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Aug 15, 2013
Genetic Services Laboratory, University of Chicago
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:3
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Oct 19, 2015
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Cardiovascular phenotype Benign:1
Dec 11, 2018
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.79
CADD
Benign
7.0
DANN
Benign
0.50
PhyloP100
0.48
Mutation Taster
=95/5
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1042396; hg19: chr17-78084769; COSMIC: COSV56407599; COSMIC: COSV56407599; API